From GlobeNewswire: 2025-03-26 16:01:00

Journey Medical Corporation announced FDA approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for rosacea. Emrosi’s Phase 3 clinical trial results were published in JAMA Dermatology, showing promising outcomes. Total revenues for the full year 2024 were $56.1 million, meeting all financial guidance. The company has started distribution, with first prescriptions filled, and anticipates full promotion in April 2025.

Financially, Journey Medical reported a net loss of $(14.7) million for 2024, compared to $(3.9) million in 2023. Key factors include a decrease in product revenue, net due to higher rebate costs and lower unit sales volumes. SG&A expenses decreased by $3.7 million, R&D expenses were $9.9 million, and the company’s cash position decreased to $20.3 million.

Recent corporate highlights include the publication of Emrosi’s Phase 3 clinical trial results and FDA approval for the treatment of rosacea. A conference call was hosted to discuss the U.S. commercial launch plan for Emrosi. In 2024, clinical data was presented comparing Emrosi to oral Doxycycline capsules. New board appointments and executive hires were made to strengthen the company’s leadership.

Adjusted EBITDA for Journey Medical in 2024 was $0.8 million, down from $15.6 million in 2023. Non-GAAP measures were used to assess the company’s performance, excluding non-cash and non-recurring items. Share-based compensation, gain on extinguishment of debt, and research and development expenses were among the factors considered in the financial analysis. The company aims to continue its growth strategy and product development programs.



Read more at GlobeNewswire:: Journey Medical Corporation Reports Full-Year 2024